Small-molecule inhibitors of p53-MDM2 interaction: The 2006-2010 update

Current Pharmaceutical Design

Volumn 17, Issue 6, 2011, Pages 536-559

  Millard, Melissa ^a   Pathania, Divya ^a   Grande, Fedora ^a   Xu, Shili ^a   Neamati, Nouri ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

AT 219; Benzodiazepinediones; cis imidazolines; JNJ 26854165; MDM2; MDM2 antagonists; Nutlin; Oxindoles; P53; P53 wild type; Protein protein interaction; RG7112; Smallmolecule anticancer agents; Spiro oxindoles; Spiroindolinone

Indexed keywords

AGENTS AFFECTING PROTEIN METABOLISM; ANTINEOPLASTIC AGENT; AT 219; BORTEZOMIB; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IMATINIB; IMIDAZOLINE DERIVATIVE; INDOLE DERIVATIVE; MI 219; MI 43; MI 63; NSC 3303; NU 8231; NU 8348; NU 8349; NU 8354; NUTLIN 3; PACLITAXEL; PROTEIN MDM2; PROTEIN P53; RG 7112; SERDEMETAN; SJ 172550; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; WK 23; WW 298;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADVANCED CANCER; ANOREXIA; BINDING AFFINITY; CHRONIC MYELOID LEUKEMIA; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FOOD DRUG INTERACTION; HEMATOLOGIC MALIGNANCY; HUMAN; HYPONATREMIA; INSOMNIA; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; QT PROLONGATION; REVIEW; SIDE EFFECT; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; VOMITING;

EID: 79953666206     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161211795222649     Document Type: Review

References (195)

1. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979; 278: 261-3.
2. Linzer DI, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979; 17: 43-52.
3. Levine AJ. The p53 tumor suppressor gene and gene product. Princess Takamatsu Symp 1989; 20: 221-30.
4. Wei CL, Wu Q, Vega VB, et al. A global map of p53 transcriptionfactor binding sites in the human genome. Cell 2006; 124: 207-19.
5. Bullock AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer 2001; 1: 68-76.
6. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-10.
7. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009; 458: 1127-30.
8. Wade M, Wang YV, Wahl GM. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 2010; 20: 299-309.
9. Cahilly-Snyder L, Yang-Feng T, Francke U, George DL. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet 1987; 13: 235-44.
10. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-9.
11. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997; 420: 25-7.
12. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387: 299-303.
13. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362: 857-60.
14. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-45.
15. Tao W, Levine AJ. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci USA 1999; 96: 3077-80.
16. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995; 378: 203-6.
17. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995; 378: 206-8.
18. Tanimura S, Ohtsuka S, Mitsui K, Shirouzu K, Yoshimura A, Ohtsubo M. MDM2 interacts with MDMX through their RING finger domains. FEBS Lett 1999; 447: 5-9.
19. Badciong JC, Haas AL. MdmX is a RING finger ubiquitin ligase capable of synergistically enhancing Mdm2 ubiquitination. J Biol Chem 2002; 277: 49668-75.
20. Linke K, Mace PD, Smith CA, Vaux DL, Silke J, Day CL. Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ 2008; 15: 841-8.
21. Shvarts A, Steegenga WT, Riteco N, et al. MDMX: a novel p53binding protein with some functional properties of MDM2. EMBO J 1996; 15: 5349-57.
22. Matheu A, Maraver A, Serrano M. The Arf/p53 pathway in cancer and aging. Cancer Res 2008; 68: 6031-4.
23. Dai MS, Lu H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J Biol Chem 2004; 279: 44475-82.
24. Dai MS, Shi D, Jin Y, Sun XX, Zhang Y, Grossman SR, Lu H. Regulation of the MDM2-p53 pathway by ribosomal protein L11 involves a post-ubiquitination mechanism. J Biol Chem 2006; 281: 24304-13.
25. Jin A, Itahana K, O'Keefe K, Zhang Y. Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol Cell Biol 2004; 24: 7669-80.
26. Meek DW, Knippschild U. Posttranslational modification of MDM2. Mol Cancer Res 2003; 1: 1017-26.
27. Kruse JP, Gu W. Modes of p53 regulation. Cell 2009; 137: 609-22.
28. Marine JC, Lozano G. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ 2010; 17: 93-102.
29. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342: 705-8.
30. Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 2006; 13: 927-34.
31. Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993; 13: 4107-14.
32. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992; 1: 45-9.
33. Soussi T, Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 2007; 12: 303-12.
34. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 2000; 275: 8945-51.
35. Kussie PH, Gorina S, Marechal V, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996; 274: 948-53.
36. Freedman DA, Epstein CB, Roth JC, Levine AJ. A genetic approach to mapping the p53 binding site in the MDM2 protein. Mol Med 1997; 3: 248-59.
37. Dickens MP, Fitzgerald R, Fischer PM. Small-molecule inhibitors of MDM2 as new anticancer therapeutics. Semin Cancer Biol 2010; 20: 10-8.
38. Glick GD, Tthe University of Michigan, USA. Novel 1,4benzodiazepine-2,5-diones with therapeutic properties. WO 2007053725 2007
39. Kamal A, Reddy KL, Devaiah V, Shankaraiah N, Reddy GSK, Raghavan S. Solid-phase synthesis of a library of pyrrolo[2,1c][1,4]benzodiazepine-5,11-diones with potential antitubercular activity. J Comb Chem 2007; 9: 29-42.
40. Cheng M-F, Fang J-M. Liquid-phase combinatorial synthesis of 1,4-benzodiazepine-2,5-diones as the candidates of endothelin receptor antagonism. J Comb Chem 2004; 6: 99-104.
41. Joseph CG, Wilson KR, Wood MS, et al. The 1,4-benzodiazepine2,5-dione small molecule template results in melanocortin receptor agonists with nanomolar potencies. J Med Chem 2008; 51: 1423-1431.
42. Cheesman EH, Sworin M, Rajopadhyem M, Du Pont Pharmaceuticals Co, USA. Preparation of vitronectin receptor antagonist pharmaceuticals. WO 2000035887 2000.
43. Cheesman EH, Barrett JA, Carpenter AP, Jr., Rajopadhye M, Sworin M, Dupont Pharmaceuticals Company, USA. Preparation of vitronectin receptor antagonist pharmaceuticals. WO 2001097861 2001.
44. Evans BE, Rittle KE, Bock MG, et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem 1988; 31: 2235-2246.
45. Francis TM, Sundberg TB, Cleary J, Groendyke T, Opipari AW, Glick GD. Identification of cytotoxic, T-cell-selective 1,4benzodiazepine-2,5-diones. Bioorg Med Chem Lett 2006; 16: 2423-2427.
46. Loudni L, Roche J, Potiron V, et al. Design, synthesis and biological evaluation of1,4-benzodiazepine-2,5-dione-based HDAC inhibitors. Bioorg Med Chem Lett 2007; 17: 4819-4823.
47. Grasberger BL, Lu T, Schubert C, et al. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem 2005; 48: 909-12.
48. Raboisson P, Marugan JJ, Schubert C, et al. Structure-based design, synthesis, and biological evaluation of novel 1,4-diazepines as HDM2 antagonists. Bioorg Med Chem Lett 2005; 15: 1857-61.
49. Deng J, Dayam R, Neamati N. Patented small molecule inhibitors of p53-MDM2 interaction. Expert Opin Ther Pat 2006; 16: 165-88.
50. Parks DJ, Lafrance LV, Calvo RR, et al. 1,4-Benzodiazepine-2,5diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR. Bioorg Med Chem Lett 2005; 15: 765-70.
51. Marugan JJ, Leonard K, Raboisson P, et al. Enantiomerically pure 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists. Bioorg Med Chem Lett 2006; 16: 3115-20.
52. Patel S, Player MR. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer. Expert Opin Investig Drugs 2008; 17: 1865-82.
53. Parks DJ, LaFrance LV, Calvo RR, et al. Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design. Bioorg Med Chem Lett 2006; 16: 3310-4.
54. Leonard K, Marugan JJ, Raboisson P, et al. Novel 1,4benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity. Bioorg Med Chem Lett 2006; 16: 3463-8.
55. Koblish HK, Zhao S, Franks CF, et al. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol Cancer Ther 2006; 5: 160-9.
56. Cummings MD, Schubert C, Parks DJ, et al. Substituted 1,4benzodiazepine-2,5-diones as alpha-helix mimetic antagonists of the HDM2-p53 protein-protein interaction. Chem Biol Drug Des 2006; 67: 201-5.
57. Huang Y, Wolf S, Bista M, et al. 1,4-Thienodiazepine-2,5-diones via MCR (I): synthesis, virtual space and p53-Mdm2 activity. Chem Biol Drug Des 2010; 76: 116-29.
58. Shangary S, Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 2008; 14: 5318-24.
59. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-8.
60. Wang Z, Jonca M, Lambros T, Ferguson S, Goodnow R. Exploration of liquid and supercritical fluid chromatographic chiral separation and purification of Nutlin-3--a small molecule antagonist of MDM2. J Pharm Biomed Anal 2007; 45: 720-9.
61. Clinical trials.gov USNIH. Chemotherapy combined with gene therapy in treating patients who have stage III or stage IV breast cancer. http://clinicaltrials.gov/ct2/show/NCT00044993
62. Stuhmer T, Chatterjee M, Hildebrandt M, et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 2005; 106: 3609-17.
63. Gu L, Zhu N, Findley HW, Zhou M. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2. Leukemia 2008; 22: 730-9.
64. Kojima K, Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005; 106: 3150-9.
65. Coll-Mulet L, Iglesias-Serret D, Santidrian AF, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in Bcell chronic lymphocytic leukemia cells. Blood 2006; 107: 4109-14.
66. Secchiero P, Barbarotto E, Tiribelli M, et al. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006; 107: 4122-9.
67. Bixby D, Kujawski L, Wang S, Malek SN. The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to MDM2 inhibitor-mediated apoptosis. Cell Cycle 2008; 7: 971-9.
68. Saddler C, Ouillette P, Kujawski L, et al. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 2008; 111: 1584-93.
69. Drakos E, Thomaides A, Medeiros LJ, et al. Inhibition of p53murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res 2007; 13: 3380-7.
70. Ohgami T, Kato K, Kobayashi H, et al. Low-dose mithramycin exerts its anticancer effect via the p53 signaling pathway and synergizes with nutlin-3 in gynecologic cancers. Cancer Sci 2010; 101: 1387-95.
71. Tseng HY, Jiang CC, Croft A, et al. Contrasting effects of nutlin-3 on TRAILand docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells. Mol Cancer Ther 2010; 9: 3363-74.
72. Zheng T, Wang J, Song X, et al. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways. J Cancer Res Clin Oncol 2010; 136: 1597-604.
73. Roh JL, Kang SK, Minn I, et al. p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma. Oral Oncol 2011; 47: 8-15.
74. Pishas KI, Al-Ejeh F, Zinonos I, et al. Nutlin-3a is a potential therapeutic for ewing sarcoma. Clin Cancer Res 2011; 17: 494-504.
75. Barbieri E, Mehta P, Chen Z, et al. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther 2006; 5: 2358-65.
76. Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 2007; 26: 3473-81.
77. Peirce SK, Findley HW. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73. Int J Oncol 2009; 34: 1395-402.
78. Zheng T, Wang J, Chen X, et al. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation. Tumour Biol 2010; 31: 287-95.
79. Michaelis M, Rothweiler F, Klassert D, et al. Reversal of Pglycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res 2009; 69: 416-21.
80. Back DJ, Tjia JF. Inhibition of tolbutamide metabolism by substituted imidazole drugs in vivo: evidence for a structureactivity relationship. Br J Pharmacol 1985; 85: 121-6.
81. Kranz D, Dobbelstein M. Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy. Cancer Res 2006; 66: 10274-80.
82. Jiang M, Pabla N, Murphy RF, et al. Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation. J Biol Chem 2007; 282: 2636-45.
83. Ooi MG, Hayden PJ, Kotoula V, et al. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res 2009; 15: 7153-60.
84. Jin L, Tabe Y, Kojima K, et al. MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53mutated mantle cell lymphoma. Cancer Lett 2010; 299: 161-70.
85. Saha MN, Jiang H, Jayakar J, Reece D, Branch DR, Chang H. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity. Cancer Biol Ther 2010; 9: 936-44.
86. Zauli G, Voltan R, Bosco R, et al. Dasatinib plus nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway. Clin Cancer Res 2011; 17: 762-70.
87. Kurosu T, Wu N, Oshikawa G, Kagechika H, Miura O. Enhancement of imatinib-induced apoptosis of BCR/ABLexpressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway. Apoptosis 2010; 15: 608-20.
88. Cao C, Shinohara ET, Subhawong TK, et al. Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2. Mol Cancer Ther 2006; 5: 411-7.
89. Lehmann BD, McCubrey JA, Jefferson HS, Paine MS, Chappell WH, Terrian DM. A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. Cell Cycle 2007; 6: 595-605.
90. Lehmann BD, McCubrey JA, Terrian DM. Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway. Cancer Biol Ther 2007; 6: 1165-70.
91. Supiot S, Hill RP, Bristow RG. Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther 2008; 7: 993-9.
92. Arya AK, El-Fert A, Devling T, et al. Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53. Br J Cancer 2010; 103: 186-95.
93. Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res 2006; 66: 3169-76.
94. Wade M, Wong ET, Tang M, Stommel JM, Wahl GM. Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem 2006; 281: 33036-44.
95. Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem 2006; 281: 33030-5.
96. Xia M, Knezevic D, Tovar C, Huang B, Heimbrook DC, Vassilev LT. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation. Cell Cycle 2008; 7: 1604-12.
97. Fotouhi N, Haley GJ, Simonsen KB, Vu BT, Webber SE, Hoffmann-La Roche Inc, USA Preparation of cis-imidazolines as anticancer drugs. US 20070167437 2007
98. Fotouhi N, Haley GJ, Simonsen KB, Vu BT, Webber SE, F.Hoffmann-La Roche AG, Switzerland, Preparation of cis-2,4,5-triaryl-imidazolines and their use as anticancer medicaments. WO2006097261 2006
99. Dominique R, Goodnow RA, Qiao Q, Vu BT, Hoffmann-Le Roche Inc., USA Preparation of diphenyldihydroimidazopyridinones which inhibit the interaction of MDM2 protein with a p53-like peptide. US 20080255119 2008
100. Ding Q, Graves BJ, Kong N, et al. Hoffmann-La Roche A.-G, Switzerland, Preparation of 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and MDM2 proteins for use as anticancer agents. WO 2007063013 2007
101. Bartkovitz DJ, Cai J, Chu XJ, Li H, et al. Hoffmann-La Roche AG, Switz, Preparation of chiral cis-imidazolines as anticancer agents. WO 2009047161 2009
102. Doemling A, University of Pittsburgh, USA Selective and dual-action p53/mdm2/mdm4 antagonists. WO 2008130614 2008 [103] Weber L. Patented inhibitors of p53-Mdm2 interaction (2006 2008). Expert Opin Ther Pat 2010; 20: 179-91.
103. Boettcher A, Buschmann N, Furet P, et al. 3-Imidazolylindoles for treatment of proliferative diseases and their preparation. WO 2008119741 2008
104. Bartkovitz DJ, Chu XJ, Ding Q, et al. Hoffmann-La Roche Inc, USA Preparation of substituted pyrrolidine-2-carboxamides as anticancer agents. US 20100152190 2010
105. Ding Q, Jiang N, Liu JJ, et al. Switzerland, Substituted pyrrolidine2-carboxamide derivatives as interaction inhibitors between P53 and MDM2 proteins and their preparation, pharmaceutical compositions and use in the treatment of cancers. WO 2010031713 2010
106. Uoto K, Sugimoto Y, Naito H, Miyazaki M, Yoshida K, Aonuma M, (Daiichi Sankyo Company,Limited, Japan). Preparation of imidazothiazole compounds containing proline moiety as Mdm2 (murine double minute 2) inhibitors. WO 2010082612 2010
107. Kawato H, Miyazaki M, Sugimoto Y, Naito H, Okayama T, Soga T, Uoto K, Daiichi Sankyo Co, Ltd, Japan, Preparation of imidazothiazole derivatives as antitumor agents. JP 2009298713 2009
108. Uoto K, Kawato H, Sugimoto Y, et al. Daiichi Sankyo Company, Limited, Japan, Preparation of imidazothiazole derivatives having 4,7-diazaspiro[2.5]octane ring structure as antitumor agents. WO 2009151069 2009
109. Puratchikody A, Doble M. Antinociceptive and anti-inflammatory activities and QSAR studies on 2-substituted-4,5-diphenyl-1Himidazoles. Bioorg Med Chem 2007; 15: 1083-1090.
110. Puratchikody A, Doble M. QSAR studies on antiepileptic and locomotor in vivo activities of 4,5-diphenyl-1H-imidazoles. Chem Biol Drug Des 2009; 74: 173-182.
111. Pivel RJP, Ferrer CJM, Fort D, Tabarez C, Moyna P, Apoteknos Para la Piel, S.L, Spain. 2,4,5-Triaryland 2-styryl-4,5-diaryl-1Himidazoles, and their preparation and use as photoprotective compositions and cosmetic treatments. WO2010146210 2010.
112. Antonchick AP, Gerding-Reimers C, Catarinella M, et al. Highly enantioselective synthesis and cellular evaluation of spirooxindoles inspired by natural products. Nat Chem 2010; 2: 735-40.
113. Brown JM, Li JJ, Sinz MW, Abraham DJ. Antipsychotic Agents. Burger's Medicinal Chemistry and Drug Discovery. 6 ed. Hoboken. John Wiley & Sons, Inc. 2003.
114. Lewis T A, Munger Karl, Howley Peter M, Koehler Angela N, Hayakawa, Hiroyuki; Neumann, Christopher, S.; Schreiber, Stuart, L. Spirooxindole Inhibitors of Aurora Kinase. WO 2008144507 2008
115. Baroni M, Puleo L, Sanofi-Aventis, Fr. Preparation of 3-substituted 3-benzofuranylindol-2-one derivatives, especially substituted N-[3-(benzofuran-5-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-2-(piperazin-1-yl)acetamide derivatives, as ghrelin receptor antagonists. WO 2010092288 2010
116. Baroni M, Puleo L, Sanofi-Aventis, Fr. Preparation of substituted N-[3-(benzofuran-5-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-2-(piperazin-1-yl)acetamide derivatives as ghrelin receptor antagonists. WO 2010092289 2010
117. Go ML, Ho HK, Zhang W. National University of Singapore, Singapore; Agency for Science, Technology and Research Preparation of3-benzylidene-indolin-2-one derivatives as modulators of protein tyrosine kinase. WO2010044753 2010.
118. Nandakumar A, Thirumurugan P, Perumal PT, Vembu P, Ponnuswamy MN, Ramesh P. ChemInform Abstract: One-Pot Multicomponent Synthesis and Antimicrobial Evaluation of 2 (Indol-3-yl)-2-oxospiro(indoline-3,4 -pyran)Derivatives. ChemInform 2010; 41: doi: 10.1002/chin.201050138.
119. Berge O-G, Claesson A, Swahn B-M, Astrazeneca AB, Swed. Preparation of spirooxindole derivatives as analgesics. WO2001005790 2001.
120. Chen L, Zhang J, Zhang Z, et al. Oxindole derivatives as anticancer agents and their preparation, pharmaceutical compositions and use in the treatment of proliferative and oncological diseases. WO 2008034736 2008.
121. Luk K-CS, Sung-Sau; Zhang, Jing; Zhang, Zhuming, Hoffman-La Roche Inc, USA Oxindole derivatives. US 7576082 B2 2009.
122. Hardcastle IR, Ahmed SU, Atkins H, et al. Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction. Bioorg Med Chem Lett 2005; 15: 1515-20.
123. Watson AF, et al. Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction 236th ACS National Meeting; August 17-21 2008 Philadelphia, PA, United States; 2008.
124. Ding K, Lu Y, Nikolovska-Coleska Z, et al. Structure-based design of potent non-peptide MDM2 inhibitors. J Am Chem Soc 2005; 127: 10130-1.
125. Ding K, Lu Y, Nikolovska-Coleska Z, et al. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem 2006; 49: 3432-5.
126. Wang S, Ding K, Lu Y, et al. Preparation of spirotryprostatin A derivatives as inhibitors of MDM2. WO 2006091646 2006
127. Sun SH, Zheng M, Ding K, Wang S, Sun Y. A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Biol Ther 2008; 7: 845-52.
128. Khan A, Lu H. Inhibition of MDM2-p53 feedback loop by various small molecules for potential cancer chemotherapy. Cancer Biol Ther 2008; 7: 853-5.
129. Shangary S, Qin D, McEachern D, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 2008; 105: 3933-8.
130. Zheng M, Yang J, Xu X, Sebolt JT, Wang S, Sun Y. Efficacy of MDM2 inhibitor MI-219 against lung cancer cells alone or in combination with MDM2 knockdown, a XIAP inhibitor or etoposide. Anticancer Res 2010; 30: 3321-31.
131. Azmi AS, Philip PA, Aboukameel A, et al. Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy. Curr Cancer Drug Targets 2010; 10: 319-31.
132. Yu S, Qin D, Shangary S, et al. Potent and orally active smallmolecule inhibitors of the MDM2-p53 interaction. J Med Chem 2009; 52: 7970-3.
133. Chen L, Ding Q, Liu JJ, Yang S, Zhang Z, Peop. Rep. China, Preparation of spiroindolinone derivatives as antitumor agents. US 20070213341 2007
134. Liu J-J, Zhang Z, F. Hoffmann-La Roche AG, Switzerland, Preparation of spiroindolepyridotriazinediones as anticancer drugs. WO 2008141975 2008
135. Chen LD, Qingjie; Liu, Jin-Jun; Yang, Song; Zhang, Zhuming, Hoffmann-La Roche Inc. USA Spiroindolinone derivatives US 7495007 B2 2009
136. Chen L, Han X, He Y, Yang S, Zhang Z, Hoffman-La Roche Inc, USA Spiroindolinone derivatives as interaction inhibitors between p53 and MDM2 proteins and their preparation, pharmaceutical compositions and use in the treatment of cancer. US 20090163512 2009
137. Ding Q, Jiang N, Yang S, Zhang J, Zhang Z, USA Preparation of 2,3-dihydrospiro[indole-3,3'-piperidine]-2,6'-dione derivatives as anticancer agents. US 20090156610 2009
138. Chen L, Han X, Yang S, Zhang Z, F. Hoffmann-La Roche AG, Switz, Preparation of 3,3'-spiroindolinones for treatment of cancer. WO 2010121995 2010
139. Zhang J, Zhang Z, USA Spiroindolinone pyridine derivatives as inhibitors of MDM2-p53 protein interaction useful as potent and selective anticancer agents and preparation thereof. US 20100210674 2010
140. Chen L, Han X, Yang S, Zhang Z, Peop. Rep. China, Spiroindolinone pyridine derivatives as inhibitors of MDM2-p53 protein interaction useful as potent and selective anticancer agents and preparation thereof. US 20100204257 2010
141. Gomez-Monterrey I, Bertamino A, Porta A, et al. Identification of the spiro(oxindole-3,3'-thiazolidine)-based derivatives as potential p53 activity modulators. J Med Chem 2010; 53: 8319-29.
142. Ding Q, LIU JJ, Zhang Z, F. Hoffmann La Roche, Basel Switzerland, Spiroindolinone Derivatives. WO 2007104714 2007 [144] Liu J-j, Tilley JW, Zhang Z, 3,3-Spiroindolinone Derivatives. US 20080287421 2008.
143. Mohammad RM, Wu J, Azmi AS, et al. An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mol Cancer 2009; 8: 115.
144. Popowicz GM, Czarna A, Wolf S, et al. Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle 2010; 9: 1104-11.
145. Popowicz GM, Czarna A, Rothweiler U, et al. Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle 2007; 6: 2386-92.
146. Popowicz GM, Czarna A, Holak TA. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle 2008; 7: 2441-3.
147. Zondlo SC, Lee AE, Zondlo NJ. Determinants of specificity of MDM2 for the activation domains of p53 and p65: proline27 disrupts the MDM2-binding motif of p53. Biochemistry 2006; 45: 11945-57.
148. Hu B, Gilkes DM, Chen J. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res 2007; 67: 8810-7.
149. Kallen J, Goepfert A, Blechschmidt A, et al. Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes. J Biol Chem 2009; 284: 8812-21.
150. Pazgier M, Liu M, Zou G, et al. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc Natl Acad Sci USA 2009; 106: 4665-70.
151. Chen J, Hu B, University of South Florida, USA Mdm2/mdmx inhibitor peptide for cancer treatment. WO 2008106507 2008
152. Czarna A, Popowicz GM, Pecak A, Wolf S, Dubin G, Holak TA. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx. Cell Cycle 2009; 8: 1176-84.
153. Stoll R, Renner C, Hansen S, et al. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 2001; 40: 336-44.
154. Khan SR, (Johns Hopkins University, USA). Boronic acid aryl analogs for the treatment of cancer. WO 2005063774 2005
155. Khan SR, Johns Hopkins University, Boronic acid aryl analogs. US 7829742 2010
156. Achanta G, Modzelewska A, Feng L, Khan SR, Huang P. A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome. Mol Pharmacol 2006; 70: 426-33.
157. Issaeva N, Bozko P, Enge M, et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004; 10: 1321-8.
158. Zhao CY, Grinkevich VV, Nikulenkov F, Bao W, Selivanova G. Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA. Cell Cycle 2010; 9: 1847-55.
159. Krajewski M, Ozdowy P, D'Silva L, Rothweiler U, Holak TA. NMR indicates that the small molecule RITA does not block p53MDM2 binding in vitro. Nat Med 2005; 11: 1135-6; author reply 1136-7.
160. Lawrence HR, Li Z, Yip ML, et al. Identification of a disruptor of the MDM2-p53 protein-protein interaction facilitated by highthroughput in silico docking. Bioorg Med Chem Lett 2009; 19: 3756-9.
161. Poncelet VS, Coupa S, Storck PH, Schoentjes B, Janssen Pharmaceutica NV, Belgium Preparation of indole derivatives as inhibitors of the interaction between mdm2 and p53 proteins. WO 2009037308 2009
162. Clinical trials.gov USNIH. A research study of JNJ-26854165 to determine the safety and dose in patients with advanced stage or refractorysolidtumors.http://clinicaltrial.gov/ct2/show/NCT00676910?term=JNJ-26854165&rank=1
163. Arts J PM, Valckx A, et al. JNJ-26854165 a novel HDM2 antagonist in clinical development showing broad-spectrum preclinical antitumour activity against solid malignancies. Proc Am Assoc Cancer Res AACR; 2008
164. Schoentjes B LJ, Meyer C. Identification of a novel orally active HDM2 antagonist with potent antitumour activity. Natl Med Chem Symp 2008
165. Poncelet AP, Schoentjes B, Storck PH, Poncelet VS, Leys C, (Janssen Pharmaceutica NV, Belg.). Preparation of substituted cyclopentapyridinylphenylenediamine derivatives for use as p53MDM2 interaction inhibitors. WO 2009019274 2009
166. Storck P-H, Schoentjes B, Piettre AMP, Ermert P, Poncelet VS, Csoka ICF, Janssen Pharmaceutica NV, Belgium, Preparation of benzoxazines and related compounds as inhibitors of p53-MDM2 interaction. WO 2009037343 2009
167. Lu Y, Nikolovska-Coleska Z, Fang X, et al. Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy. J Med Chem 2006; 49: 3759-62.
168. Schimmer AD. Clioquinol a novel copper-dependent and independent proteasome inhibitor. Curr Cancer Drug Targets 2011.
169. Mao X, Schimmer AD. The toxicology of Clioquinol. Toxicol Lett 2008; 182: 1-6.
170. Ma Y, Lahue BR, Shipps GW, et al. Schering Corporation, USA Preparation of substituted piperidines that increase p53 activity and the uses thereof. US 20080004287 2008
171. Hesson TEL, Hung V, Ma Yao, Madison Vincent S, Mannarino, Anthony F.; Reichert, Paul; Shipps, Jr, Gerald W.; Strickland, Corey O.;Taremi, Shahriar Shane; Wang, Yaolin; Zhang, Rumin; Duca, Jose, Schering Corporation, USA HDM2 Polypeptides US 7705127 B1 2010
172. Sakurai K, Kahne D. Design and Synthesis of Functionalized Trisaccharides as p53-Peptide Mimics. Tetrahedron Lett 2010; 51: 3724-3727.
173. Czarna A, Beck B, Srivastava S, et al. Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists. Angew Chem Int Ed Engl 2010; 49: 5352-6.
174. Lai Z, Yang T, Kim YB, et al. Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors. Proc Natl Acad Sci USA 2002; 99: 14734-9.
175. Davydov IV, Woods D, Safiran YJ, et al. Assay for ubiquitin ligase activity: high-throughput screen for inhibitors of HDM2. J Biomol Screen 2004; 9: 695-703.
176. Murray MF, Jurewicz AJ, Martin JD, et al. A high-throughput screen measuring ubiquitination of p53 by human mdm2. J Biomol Screen 2007; 12: 1050-8.
177. Yang Y, Ludwig RL, Jensen JP, et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 2005; 7: 547-59.
178. Kitagaki J, Agama KK, Pommier Y, Yang Y, Weissman AM. Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2. Mol Cancer Ther 2008; 7: 2445-54.
179. Allen JG, Bourbeau MP, Wohlhieter GE, et al. Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction. J Med Chem 2009; 52: 7044-53.
180. Reed D, Shen Y, Shelat AA, et al. Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem 2010; 285: 10786-96.
181. Rebek J, Jr, Moisan L, The Scripps Research Institute, USA Preparation of pyridazine derivatives as-helix scaffolds for disruption of protein-protein interaction. WO 2010042758 2010
182. Kojima K, Burks JK, Arts J, Andreeff M. The novel tryptamine derivative JNJ-26854165 induces wild-type p53and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. Mol Cancer Ther 2010; 9: 2545-57.
183. Stühmer T, Arts J, King P, et al. A first-in-class HDM2-inhibitor (JNJ-26854165) in phase I development shows potent activity against multiple myeloma (MM) cell in vitro and ex vivo. ASCO Annual Meeting; 2008
184. Jones RJ, Arts J, Orlowski RZ. Inhibition of the human double minute(HDM)-2 E3 ubiquitin ligase activates different programmed cell death (PCD) pathways in models of Non-Hodgkin lymphoma (NHL) with wild type (wt) and mutant (mut) p53. 50th ASH Annual Meeting and Exposition; San Francisco; 2008
185. Arts J, Smans K, Andries L, et al. Preclinical and clinical pharmacodynamic activity of JNJ-26854165: a novel HDM2 antagonist in clinical development. 100th AACR Annual Meeting; Denver; 2009
186. Clinical trials.gov USNIH. A phase I study to determine the safety, pharmacology, and pharmacodynamics of JNJ26854165 in subjects with advanced stage and/or refractory solid tumors. http://clinicaltrials.gov/ct2/show/record/NCT00676910
187. Tabernero J, Dirix L, Schöffski P, et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of HDM-2 antagonist JNJ-26854165 in patients with advanced refractory solid tumors. ASCO Annual Meeting; 2009
188. Tabernero J, Schöffski P, Dirix L, et al. First-in-human study of the first-in-class HDM2 inhibitor JNJ-26854165.20th EORTC-NCIAACR Symposium on molecular targets and cancer therapeutics; Geneva, Switzerland; 2008
189. Huntjens DR, Beijsterveldt LV, Kraljevic S. Pharmacokineticpharmacodynamic(PK-PD) modeling and simulation of serdemetan-induced QTc effects in a first-in-human study. ASCO Annual Meeting; 2010
190. Wang W, Hu Y. Small molecule agents targeting the p53-MDM2 pathway for cancer therapy. Med Res Rev 2011; DOI: 10.1002/ med.20236.
191. Clinical trials.gov USNIH. A multi-center, open-label, phase I study of single agent R7112 administered orally in patients with advanced malignancies, except all forms of leukaemia. http://clinicaltrials.gov/ct2/show/record/NCT00559533?term=RO5045337&rank=4
192. Clinical trials.gov USNIH. An open label study to investigate the maximum tolerated dose of R7112 in patients with acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML) in blast phase, or refractory chronic lymphocytic leukemia/small cell lymphocytic lymphoma(CLL/SCLL). http://clinicaltrials.gov/ct2/show? term=RO5045337&rank=3
193. Andreeff M, Kojima K, Padmanabhan S, et al. A multi-center, open-label, phase I study of single agent RG7112, a first in class p53-MDM2 antagonist, in patients with relapsed/refractory acute myeloid and lymphoid leukemias (AML/ALL) and refractory chronic lymphocytic leukemia/small cell lymphocytic lymphomas (CLL/SCLL). 52nd ASH Annual Meeting and Exposition; Orlando; 2010
194. Clinical trials.gov USNIH. An exploratory biomarker study of RO5045337 in patients with liposarcomas prior to debulking surgery. http://clinicaltrials.gov/ct2/show?term=RO5045337&rank=2
195. Clinical trials.gov USNIH. An open-label, randomized 3-way crossover, study to examine the food-effect on pharmacokinetics of the current formulation and relative bioavailability of two new formulations for RO5045337 in patients with solid tumors includinglymphoma. http://clinicaltrials.gov/ct2/show?term=RO5045337&rank=1